FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976571856> ?p ?o ?g. }

• W1976571856 endingPage "100" @default.
• W1976571856 startingPage "94" @default.
• W1976571856 abstract "Objective and designThe study aimed at assessing the therapeutic efficacy and safety of metadoxine versus placebo on the ultrasonographic and histological features of non-alcoholic steatohepatitis (NASH).Subjects134 subjects with biopsy-confirmed NASH were randomized to receive metadoxine 500 mg two times daily (n = 75) or placebo (n = 59) added to the standard of care, over 16 weeks.Efficacy endpointsOriginally, the primary efficacy endpoint was the composite of: reduction in the steatosis by ≥1 grade, reduction in hepatic necro-inflammation by ≥1 grade and ALT normalization. Since >50% of patients refused the second biopsy, it was decided to analyze only the individual parameters.ResultsThere was no significant difference between the treatment and the placebo groups in either liver histology or ALT or AST. Overall, as expected both groups showed reduction in serum ALT and AST compared to baseline. Compared to placebo (9 out 54), patients on metadoxine (34 out of 75) had significantly higher rates of improvement in 1-point in steatosis grade on ultrasound (P-value <0.001). Safety and tolerability did not differ between treatments.ConclusionMetadoxine is not effective in improvement of liver histology or serum ALT or AST in patients with NASH. However, there was significant improvement of steatosis assessed by ultrasound. To properly estimate the effects on histology and transaminases, further studies of longer duration and at higher doses are needed. The study aimed at assessing the therapeutic efficacy and safety of metadoxine versus placebo on the ultrasonographic and histological features of non-alcoholic steatohepatitis (NASH). 134 subjects with biopsy-confirmed NASH were randomized to receive metadoxine 500 mg two times daily (n = 75) or placebo (n = 59) added to the standard of care, over 16 weeks. Originally, the primary efficacy endpoint was the composite of: reduction in the steatosis by ≥1 grade, reduction in hepatic necro-inflammation by ≥1 grade and ALT normalization. Since >50% of patients refused the second biopsy, it was decided to analyze only the individual parameters. There was no significant difference between the treatment and the placebo groups in either liver histology or ALT or AST. Overall, as expected both groups showed reduction in serum ALT and AST compared to baseline. Compared to placebo (9 out 54), patients on metadoxine (34 out of 75) had significantly higher rates of improvement in 1-point in steatosis grade on ultrasound (P-value <0.001). Safety and tolerability did not differ between treatments. Metadoxine is not effective in improvement of liver histology or serum ALT or AST in patients with NASH. However, there was significant improvement of steatosis assessed by ultrasound. To properly estimate the effects on histology and transaminases, further studies of longer duration and at higher doses are needed." @default.
• W1976571856 created "2016-06-24" @default.
• W1976571856 creator A5008486409 @default.
• W1976571856 creator A5018671856 @default.
• W1976571856 creator A5018749661 @default.
• W1976571856 creator A5020213227 @default.
• W1976571856 creator A5021031317 @default.
• W1976571856 creator A5024998955 @default.
• W1976571856 creator A5038965789 @default.
• W1976571856 creator A5041076681 @default.
• W1976571856 creator A5079007546 @default.
• W1976571856 creator A5090297641 @default.
• W1976571856 date "2014-06-01" @default.
• W1976571856 modified "2023-09-30" @default.
• W1976571856 title "Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial" @default.
• W1976571856 cites W110415351 @default.
• W1976571856 cites W1639691091 @default.
• W1976571856 cites W1868475579 @default.
• W1976571856 cites W1963682935 @default.
• W1976571856 cites W1964078018 @default.
• W1976571856 cites W2004177180 @default.
• W1976571856 cites W2016530231 @default.
• W1976571856 cites W2021738092 @default.
• W1976571856 cites W2022296797 @default.
• W1976571856 cites W2023564878 @default.
• W1976571856 cites W2025680761 @default.
• W1976571856 cites W2039963918 @default.
• W1976571856 cites W2043066225 @default.
• W1976571856 cites W2054026627 @default.
• W1976571856 cites W2080800289 @default.
• W1976571856 cites W2087829753 @default.
• W1976571856 cites W2101468685 @default.
• W1976571856 cites W2129074280 @default.
• W1976571856 cites W2335960099 @default.
• W1976571856 cites W2395831723 @default.
• W1976571856 cites W2396586125 @default.
• W1976571856 cites W2397968011 @default.
• W1976571856 cites W2400063684 @default.
• W1976571856 cites W2405846450 @default.
• W1976571856 cites W2410800887 @default.
• W1976571856 cites W2426847434 @default.
• W1976571856 cites W2433810498 @default.
• W1976571856 cites W4200928 @default.
• W1976571856 cites W2337039709 @default.
• W1976571856 doi "https://doi.org/10.1016/j.jceh.2014.03.041" @default.
• W1976571856 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4116708" @default.
• W1976571856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25755546" @default.
• W1976571856 hasPublicationYear "2014" @default.
• W1976571856 type Work @default.
• W1976571856 sameAs 1976571856 @default.
• W1976571856 citedByCount "15" @default.
• W1976571856 countsByYear W19765718562016 @default.
• W1976571856 countsByYear W19765718562018 @default.
• W1976571856 countsByYear W19765718562019 @default.
• W1976571856 countsByYear W19765718562020 @default.
• W1976571856 countsByYear W19765718562021 @default.
• W1976571856 countsByYear W19765718562022 @default.
• W1976571856 crossrefType "journal-article" @default.
• W1976571856 hasAuthorship W1976571856A5008486409 @default.
• W1976571856 hasAuthorship W1976571856A5018671856 @default.
• W1976571856 hasAuthorship W1976571856A5018749661 @default.
• W1976571856 hasAuthorship W1976571856A5020213227 @default.
• W1976571856 hasAuthorship W1976571856A5021031317 @default.
• W1976571856 hasAuthorship W1976571856A5024998955 @default.
• W1976571856 hasAuthorship W1976571856A5038965789 @default.
• W1976571856 hasAuthorship W1976571856A5041076681 @default.
• W1976571856 hasAuthorship W1976571856A5079007546 @default.
• W1976571856 hasAuthorship W1976571856A5090297641 @default.
• W1976571856 hasBestOaLocation W19765718562 @default.
• W1976571856 hasConcept C126322002 @default.
• W1976571856 hasConcept C142724271 @default.
• W1976571856 hasConcept C168563851 @default.
• W1976571856 hasConcept C197934379 @default.
• W1976571856 hasConcept C203092338 @default.
• W1976571856 hasConcept C204787440 @default.
• W1976571856 hasConcept C27081682 @default.
• W1976571856 hasConcept C2775934546 @default.
• W1976571856 hasConcept C2776175330 @default.
• W1976571856 hasConcept C2777766500 @default.
• W1976571856 hasConcept C2778375690 @default.
• W1976571856 hasConcept C2778772119 @default.
• W1976571856 hasConcept C2779134260 @default.
• W1976571856 hasConcept C2779478299 @default.
• W1976571856 hasConcept C71924100 @default.
• W1976571856 hasConcept C90924648 @default.
• W1976571856 hasConceptScore W1976571856C126322002 @default.
• W1976571856 hasConceptScore W1976571856C142724271 @default.
• W1976571856 hasConceptScore W1976571856C168563851 @default.
• W1976571856 hasConceptScore W1976571856C197934379 @default.
• W1976571856 hasConceptScore W1976571856C203092338 @default.
• W1976571856 hasConceptScore W1976571856C204787440 @default.
• W1976571856 hasConceptScore W1976571856C27081682 @default.
• W1976571856 hasConceptScore W1976571856C2775934546 @default.
• W1976571856 hasConceptScore W1976571856C2776175330 @default.
• W1976571856 hasConceptScore W1976571856C2777766500 @default.
• W1976571856 hasConceptScore W1976571856C2778375690 @default.
• W1976571856 hasConceptScore W1976571856C2778772119 @default.
• W1976571856 hasConceptScore W1976571856C2779134260 @default.

• next